The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“High-Grade Glioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.
Some of the key takeaways from the High-Grade Glioma Pipeline Report:
-
Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years.
-
High-Grade Glioma companies working in the treatment market are Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others, are developing therapies for the High-Grade Glioma treatment
-
Emerging High-Grade Glioma therapies in the different phases of clinical trials are- ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.
-
In August 2024, Predictive diagnostics company Kiyatec has revealed data demonstrating that its 3D Predict Glioma test enhances survival outcomes for patients with high-grade glioma (HGG) by accurately forecasting their response to chemotherapy. Published in Scientific Reports, the findings show that test responders experienced a median progression-free survival extension of 5.8 months and an overall survival increase of 7.6 months compared to non-responders. The study (NCT03561207) included 102 patients newly diagnosed with HGG, a cancer known for its poor prognosis.
-
In May 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110. This next-generation oncolytic viral immunotherapy is intended for treating recurrent high-grade glioma (rHGG). Glioblastoma (GBM), the most prevalent and aggressive type of high-grade glioma, remains a significant therapeutic challenge.
-
In April 2024, Denovo Biopharma LLC (Denovo), a leader in utilizing precision medicine for developing innovative treatments, has announced that the California Institute for Regenerative Medicine (CIRM) has granted $11.8 million for the continued advancement of DB107. This is Denovo's DGM7™ biomarker-guided late-stage gene therapy aimed at high-grade glioma (HGG), including glioblastoma (GBM), a type of malignant brain cancer. The grant has been awarded to Dr. Noriyuki Kasahara, MD, PhD, at the University of California San Francisco (UCSF), along with a team of researchers from California universities, to conduct a Phase 1/2 clinical trial evaluating DB107 in patients newly diagnosed with HGG.
High-Grade Glioma Overview
High-grade glioma (HGG) refers to a group of aggressive brain tumors that originate from glial cells, which provide support and protection for neurons. These tumors are classified as high-grade due to their rapid growth and tendency to invade surrounding brain tissue, making them difficult to treat. The most common type of HGG is glioblastoma multiforme (GBM), characterized by its heterogeneous cellular makeup and resistance to therapy. Symptoms of HGG can include headaches, seizures, cognitive changes, and neurological deficits, depending on the tumor's location in the brain. Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, but the prognosis remains poor, with limited survival rates.
Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight
Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:
-
ONC201: Chimerix
-
BMX-001: BioMimetix
-
OKN-007: Oblato, Inc.
-
Lisavanbulin: Basilea Pharmaceutica
-
Terameprocol: Erimos Pharmaceuticals
-
Zotiraciclib: Adastra Pharmaceuticals/S*Bio
-
PTC596: PTC Therapeutics
-
OS2966: OncoSynergy
-
CAN 3110: Candel Therap
-
DSP 0390: Sumitomo Pharma Oncology, Inc.
-
Terameprocol: Erimos Pharmaceuticals
-
Lenvatinib: Eisai Inc.
-
PVSRIPO: Istari Oncology, Inc.
-
BMX-001: BioMimetix Pharma
High-Grade Glioma Route of Administration
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Infusion
-
Intradermal
-
Intramuscular
-
Intranasal
-
Intravenous
-
Oral
-
Parenteral
-
Subcutaneous
-
Molecule Type
High-Grade Glioma Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types, such as
-
Gene therapies
-
Small molecule
-
Vaccines
-
Polymers
-
Peptides
-
Monoclonal antibodies
-
Product Type
High-Grade Glioma Pipeline Therapeutics Assessment
-
High-Grade Glioma Assessment by Product Type
-
High-Grade Glioma By Stage and Product Type
-
High-Grade Glioma Assessment by Route of Administration
-
High-Grade Glioma By Stage and Route of Administration
-
High-Grade Glioma Assessment by Molecule Type
-
High-Grade Glioma by Stage and Molecule Type
DelveInsight's High-Grade Glioma Report covers around 150+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies
Some of the key companies in the High-Grade Glioma Therapeutics Market include:
Key companies developing therapies for High-Grade Glioma are - Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.
High-Grade Glioma Pipeline Analysis:
The High-Grade Glioma pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.
-
High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies
High-Grade Glioma Pipeline Market Drivers
-
Increasing the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.
High-Grade Glioma Pipeline Market Barriers
-
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.
Scope of High-Grade Glioma Pipeline Drug Insight
-
Coverage: Global
-
Key High-Grade Glioma Companies: Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others
-
Key High-Grade Glioma Therapies: ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others
-
High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies
-
High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers
Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials
Table of Contents
1. High-Grade Glioma Report Introduction
2. High-Grade Glioma Executive Summary
3. High-Grade Glioma Overview
4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment
5. High-Grade Glioma Pipeline Therapeutics
6. High-Grade Glioma Late Stage Products (Phase II/III)
7. High-Grade Glioma Mid Stage Products (Phase II)
8. High-Grade Glioma Early Stage Products (Phase I)
9. High-Grade Glioma Preclinical Stage Products
10. High-Grade Glioma Therapeutics Assessment
11. High-Grade Glioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. High-Grade Glioma Key Companies
14. High-Grade Glioma Key Products
15. High-Grade Glioma Unmet Needs
16 . High-Grade Glioma Market Drivers and Barriers
17. High-Grade Glioma Future Perspectives and Conclusion
18. High-Grade Glioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
